3De Berardis D, Valchera A, Fornaro M, et al. Agomela- tine reversal of escitalopram-induced apathy: a case report [J]. Psychiatry Clin Neurosci, 2013,67 ( 3 ) : 190.
4Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder[J]. Expert Opin Pharmacoth- er,2011,12(15) :2 411.
5Srinivasan V, Zakaria R, Othman Z, et al. Agomelatine in depressive disorders: its novel mechanisms of action [J]. J Neuropsychiatty Clin Neurosci, 2012,24 (3) : 290.
6Courtet P, Olid E. Circadian dimension and severity of de- pression[J].Eur Neuropsychopharmacol, 2012, 22 (Suppl 3) : S476.
7Lam RW. Onset, time course and trajectories of improve- ment with antidepressants[J]. Eur Neuropsychopharma- col, 2012,22 (Suppl 3) : S492.
8Tiuvina NA, Smirnova VN. A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent de-pression and bipolar affective disorder[J]. Zh Nevrol Psikhiatr lm S S Korsakova , 2 012,112 ( 11 ) : 5 3.
9Pizova NV.Valdoxan (agomelatine) in the treatment of de- pression in patients with cerebrovascular diseases: the re- suits of the Russian multicenter naturalistic study "Reso- nance" [J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2012, 112(12):41.
10Gorwood P, Bayle F, Vaiva G, et al. Is it worth assessing progress as early as week 2 to adapt antidepressive treat- ment strategy? Results from a study on agomelatine and a global meta-analysis[J]. Eur Psychiatry, 2013,28 (6):362.
